Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C14H14N2.ClH |
| Molecular Weight | 246.735 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C(C1=NCCN1)C2=C3C=CC=CC3=CC=C2
InChI
InChIKey=DJDFFEBSKJCGHC-UHFFFAOYSA-N
InChI=1S/C14H14N2.ClH/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14;/h1-7H,8-10H2,(H,15,16);1H
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C14H14N2 |
| Molecular Weight | 210.2744 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.drugbank.ca/drugs/DB06711Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/naphazoline.html
Sources: http://www.drugbank.ca/drugs/DB06711
Curator's Comment: Description was created based on several sources, including
https://www.drugs.com/pro/naphazoline.html
Naphazoline is a direct acting sympathomimetic adrenergic alpha-agonist used to induce systemic vasoconstriction, thereby decreasing nasal congestion and inducing constriction around the conjunctiva. The sympathomimetic action of Naphazoline constricts the smaller arterioles of the nasal passages, producing a decongesting effect. Naphazoline ophthalmic causes constriction of blood vessels in the eyes. It also decreases itching and irritation of the eyes. aphazoline constricts the vascular system of the conjunctiva. It is presumed that this effect is due to direct stimulation action of the drug upon the alpha adrenergic receptors in the arterioles of the conjunctiva resulting in decreased conjunctival congestion. Naphazoline belongs to the imidazoline class of sympathomimetics. Naphazoline is a direct acting sympathomimetic drug, which acts on alpha-adrenergic receptors in the arterioles of the nasal mucosa. This activates the adrenal system to yield systemic vasoconstrction. In producing vasoconstriction, the result is a decrease in blood flow in the nasal passages and consequently decreased nasal congestion. The vasoconstriction means that there is less pressure in the capillaries and less water can filter out, thus less discharge is made. Naphazoline is primarily indicated in conditions like Corneal vascularity, Hyperaemia, Itching, Nasal congestion, and can also be given in adjunctive therapy as an alternative drug of choice in Sinusitis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3021557
Curator's Comment: poorly crosses the blood-brain barrier
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL229 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11597419 |
63.1 nM [EC50] | ||
Target ID: CHEMBL232 Sources: https://www.ncbi.nlm.nih.gov/pubmed/11597419 |
5.0 µM [EC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Naphazoline Hydrochloride Approved UseNaphazoline Hydrochloride Ophthalmic Solution is indicated for use as a topical ocular vasoconstrictor. Launch Date1974 |
Doses
| Dose | Population | Adverse events |
|---|---|---|
0.25 mg/mL 2 times / day multiple, topical Recommended Dose: 0.25 mg/mL, 2 times / day Route: topical Route: multiple Dose: 0.25 mg/mL, 2 times / day Sources: |
unhealthy, 35±15 |
Disc. AE: Burning sensation... AEs leading to discontinuation/dose reduction: Burning sensation (6.7%) Sources: |
2 drop 8 times / day multiple, topical Highest studied dose Dose: 2 drop, 8 times / day Route: topical Route: multiple Dose: 2 drop, 8 times / day Sources: |
healthy Health Status: healthy Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Burning sensation | 6.7% Disc. AE |
0.25 mg/mL 2 times / day multiple, topical Recommended Dose: 0.25 mg/mL, 2 times / day Route: topical Route: multiple Dose: 0.25 mg/mL, 2 times / day Sources: |
unhealthy, 35±15 |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as perpetrator
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18493746/ |
no |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Identification and characterization of platelet α2-adrenoceptors and imidazoline receptors in rats, rabbits, cats, dogs, cattle, and horses. | 2013-11-15 |
|
| Spectroscopic analyses on interaction of Naphazoline hydrochloride with bovine serum albumin. | 2012-12 |
|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Simultaneous determination of antazoline and naphazoline by the net analyte signal standard addition method and spectrophotometric technique. | 2011-02-15 |
|
| Pulmonary edema and prolonged awakening after nasal naphazoline application in a transspenoidal hypophysectomy patient. | 2010-07 |
|
| Structural and functional evolution of the trace amine-associated receptors TAAR3, TAAR4 and TAAR5 in primates. | 2010-06-15 |
|
| Functional and pharmacological characterization of a beta-adrenergic-like octopamine receptor from the silkworm Bombyx mori. | 2010-06 |
|
| [Microhemocirculation and its correction in duodenal ulcer during period of rehabilitation]. | 2010-05-12 |
|
| Synthesis, anticonvulsant and antimicrobial activities of some new 2-acetylnaphthalene derivatives. | 2010-04-15 |
|
| Treatment of allergic conjunctivitis: results of a 1-month, single-masked randomized study. | 2010-04-13 |
|
| Pharmacological characterization of a Bombyx mori alpha-adrenergic-like octopamine receptor stably expressed in a mammalian cell line. | 2010-02 |
|
| Determination of tetrahydrozoline in urine and blood using gas chromatography-mass spectrometry (GC-MS). | 2010 |
|
| Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines. | 2009-08-31 |
|
| A comparative kinetic and mechanistic study between tetrahydrozoline and naphazoline toward photogenerated reactive oxygen species. | 2009-08-28 |
|
| Nasal irrigation with lavonase as ancillary treatment of acute rhinosinusitis: a pilot study. | 2009-07-11 |
|
| Allergic contact dermatitis from dibucaine hydrochloride, chlorpheniramine maleate, and naphazoline hydrochloride in an over-the-counter topical antiseptic. | 2009-07 |
|
| Effect of subconjunctival bevacizumab on primary pterygium. | 2009-05 |
|
| Influence of the ageing phenomenon on the low-frequency electrical impedance behavior of naphazoline hydrochloride solutions and paracetamol syrup. | 2009-05 |
|
| Flow-injection chemiluminescence method for the determination of naphazoline hydrochloride and oxymetazoline hydrochloride. | 2009-03-03 |
|
| [Peritopic anesthesia in cataract surgery]. | 2009-02 |
|
| Intranasal lidocaine plus naphazoline nitrate improves surgical conditions and perioperative analgesia in septorhinoplasty surgery. | 2009-02 |
|
| A presentation of longstanding toxoplasmosis chorioretinitis. | 2009-01 |
|
| Successful endonasal dacryocystorhinostomy in a patient with Wegener's granulomatosis. | 2009 |
|
| Simultaneous determination of dibucaine and naphazoline in human serum by monolithic silica spin column extraction and liquid chromatography-mass spectrometry. | 2008-09-01 |
|
| In vitro culturing of porcine tracheal mucosa as an ideal model for investigating the influence of drugs on human respiratory mucosa. | 2008-09 |
|
| Relationship between rhinitis duration and response to nasal decongestion test. | 2008-07 |
|
| Acute pulmonary edema associated with naphazoline ingestion. | 2008-03 |
|
| [The influence of different alpha-sympathomimetic drugs and benzalkoniumchlorid on the ciliary beat frequency of in vitro cultured human nasal mucosa cells]. | 2008-01 |
|
| UV-Vis spectrophotometrical and analytical methodology for the determination of singlet oxygen in new antibacterials drugs. | 2007-11-11 |
|
| Ischemic stroke in a man with naphazoline abuse history. | 2007-10 |
|
| Ebastine improves nasal symptoms and airflow and affects response to decongestion test in patients with persistent allergic rhinitis: a pilot study. | 2007-09-22 |
|
| The pK(a) Distribution of Drugs: Application to Drug Discovery. | 2007-09-17 |
|
| Nasal eosinophils and reversibility to the decongestion test in patients with perennial allergic rhinitis. | 2007-07-11 |
|
| Eyelid ptosis from sympathetic nerve dysfunction mistaken as myopathy: a simple test to identify this condition. | 2007-06 |
|
| Theoretical assessment of naphazoline redoxchemistry and photochemistry. | 2007-04-19 |
|
| Rhinoplasty - indications and techniques. | 2007 |
|
| Naphazoline intoxication in children. | 2006-11 |
|
| Fast simultaneous spectrophotometric determination of naphazoline nitrate and methylparaben by sequential injection chromatography. | 2006-09-15 |
|
| Different mechanisms between thromboxane A2- and leukotriene D4-induced nasal blockage in guinea pigs. | 2006-09 |
|
| Antagonism by imidazoline-type drugs of muscarinic and other receptors in the guinea-pig ileum. | 2006-07 |
|
| Do topical nasal decongestants affect polyps? | 2006-03 |
|
| Association between response to decongestion testing and sensitizations and allergic inflammation. | 2006-03 |
|
| Evaluation, in vitro, of the radioprotection of DNA from gamma-rays by naphazoline. | 2006-03 |
|
| Net analyte signal-based simultaneous determination of antazoline and naphazoline using wavelength region selection by experimental design-neural networks. | 2006-02-15 |
|
| The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data. | 2004-02-27 |
|
| Actual therapeutic management of allergic and hyperreactive nasal disorders. | 2004 |
|
| Radioprotective Activity and Synthesis of Siladithioacetals and Germadithioacetals Derived from N-substituted Naphthylethylimidazoline. | 2001 |
|
| Selective inhibition of alpha1B-adrenergic receptor expression and function using a phosphorothioate antisense oligodeoxynucleotide. | 1998-06 |
|
| The influence of alpha-adrenergic drugs on catalepsy induced by haloperidol or fluphenazine in rats. | 1978-09-01 |
|
| Central action of narcotic analgesics. Part IV. Noradrenergic influences on the activity of analgesics in rats. | 1978-09-01 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/pro/naphazoline.html
Instill one or two drops in the conjunctival sac(s) every three to four hours as needed.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12037379
Naphazoline (1, 10, and 100 umol/l) caused a dose-related inhibition of NE release from ICBs (iris-ciliary body) of the rabbit eye: 25, 45, and 80%, respectively.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:48:50 GMT 2025
by
admin
on
Mon Mar 31 17:48:50 GMT 2025
|
| Record UNII |
MZ1131787D
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
CFR |
21 CFR 349.18
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
CFR |
21 CFR 341.20
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
||
|
NCI_THESAURUS |
C29709
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
82054
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID7045788
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
DBSALT000127
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
100000090391
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
2174
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
208-989-2
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
m7723
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | Merck Index | ||
|
C47632
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
1457006
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
SUB03389MIG
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
550-99-2
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
MZ1131787D
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
35711
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
11079
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
CHEMBL761
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY | |||
|
MZ1131787D
Created by
admin on Mon Mar 31 17:48:50 GMT 2025 , Edited by admin on Mon Mar 31 17:48:50 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|